US jury verdict on validity of Pfizer's Protonix patent puts at-risk launches in spotlight
This article was originally published in Scrip
Executive Summary
Pfizer has been handed a significant patent victory by a federal court jury, which upheld the validity of the main US patent covering the company's gastroesophageal reflux disease (GORD) treatment Protonix (pantoprazole). The jury rejected claims by generic drug makers that the patent was obvious.